AstraZeneca subsidiary MedImmune indicators an unique permit arrangement with South Korean’s Alteogen. The goal is to create subcutaneous therapy options for cancer cells individuals.
发布者:BY ULRICH QUISTGAARD,转转请注明出处:https://robotalks.cn/astrazeneca-to-develop-new-cancer-drugs-via-south-korean-deal/